Loxo buy a step closer to paying off as Lilly heads to FDA with RET inhibitor

Lilly could have the best-in-class and first-in-class RET fusion inhibitor as it heads to FDA this year with the lead asset in its $8 billion acquisition of Loxo Oncology Inc.

Eli Lilly and Co. (NYSE:LLY) announced data on Monday from the Phase

Read the full 417 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE